MedTrace Logo

Steroid Eye Drops in Chronic Central Serous Chorioretinopathy

NCT05633576 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-04-11

No results posted yet for this study

Summary

In this pilot study the effect and safety of the use of steroid eye drops in chronic central serous chorioretinopathy (cCSC) will be evaluated. The study is conducted as a randomized single-blind placebo-controlled trial. Forty patients will be randomized to either steroid eye drops or placebo eye drops. Patients will self-administer the eye drops three times a day for four weeks.

Conditions

  • Chronic Central Serous Chorioretinopathy

Interventions

DRUG

steroid eye drops

Self-administration of steroid eye drops three times a day for four consecutive weeks.

DRUG

Placebo

Self-administration of placebo eye drops three times a day for four consecutive weeks.

Sponsors & Collaborators

  • Oogziekenhuis Rotterdam

    collaborator OTHER

  • Radboud University Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-19
Primary Completion
2025-06-19
Completion
2025-07-19

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05633576 on ClinicalTrials.gov